Clinical trial evaluation is a key step to translating research into new medicines that can provide better outcomes for patients. Currently, only about 3-5% of U.S. adults with cancer participate in clinical trials. This is unacceptable – we need to increase participation!
As part of the National Moonshot Summit earlier this year, the National Brain Tumor Society (NBTS) announced its commitment to launching a major patient and caregiver engagement and education initiative to increase the focus on patient-centered treatment development, with a particular emphasis on clinical trial participation among brain cancer patients.
As a result, we have launched a new survey to collect information about patient and caregiver perceptions concerning brain tumor clinical trials to ensure our initiative meets the needs of our community.
To accurately represent your experience and let your voice be heard, please complete this survey. Your responses are completely anonymous and it should only take about 15 minutes of your time.
The goals of this survey are to:
- Determine if, when, and how information is provided to patients and caregivers about clinical trials
- Understand, from a patient and caregiver perspective, the factors that would influence participation in a brain tumor clinical trial.
A critical amount of quality trial data is required prior to FDA submission and without a sufficient amount of willing patients (and investigators), new drugs cannot be approved. Despite widespread public acknowledgement of the contribution clinical trials have on the progress in the fight against cancer, a limited number of patients are actually participating. This leads to consequences such as prolonged duration of clinical trials, delayed analysis of results, increased costs for study completion, termination of studies, and hindrance to patient access to new therapies.
We appreciate you taking the time to complete our survey.